MYC translocation is a valuable marker for the development and relapse of extramedullary disease in multiple myeloma

• DOI: 10.1111/ejh.14296
• Publication Date: 2024-08-28T02:29:15Z
• Authors: Yuhang Song; Jianhua Du; Xianghong Jin; Hui Li; Congwei Jia; Yuanyuan Liu; Kaimi Li; Daobin Zhou; Junling Zhuang
• Keywords: 03 medical and health sciences; 0302 clinical medicine

Abstract Objective To study the cytogenetic characteristics of extramedullary disease (EMD) in patients with multiple myeloma (MM) and their impact on prognosis. Methods Patients newly diagnosed MM (NDMM) at Peking Union Medical College Hospital (Beijing, China) between June 2007 December 2019 were recruited for this study. Demographic information, clinical data, fluorescence situ hybridization (FISH) results marrow tissue samples, survival outcome data collected. Results A total 439 NDMM divided into those without EMD (non‐EMD, n = 339), primary paraosseous plasmacytoma (pEMD‐B, 48), soft‐tissue involvement (pEMD‐S, 33), secondary (sEMD, 19). The incidence was 18.5% (81/439) diagnosis 22.8% (100/439) throughout course. Comparison FISH showed a higher proportion RB1 deletion ( 20; 60.0% vs. 20.0%, p .013) MYC translocation 12; 44.4% 12.5%, .041) tissues than paired bone samples. At diagnosis, percentage translocations sEMD group notably that non‐EMD (55.6% 15.5%, .012). median overall (OS) pEMD‐S (32 months) (17 significantly shorter (both .001) (60 months). Conclusion Soft‐tissue can be considered high‐risk condition, even era novel agents. serve as valuable marker correlates spread relapse should inclusion routine panels practice.